Myriad Genetics | MYGN - Debt


Myriad Genetics reported $59.3M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Agilent USD 3.36B 1000K Mar/2026
Becton, Dickinson and Co. USD 17.28B 2.26B Mar/2026
Bio-Rad Laboratories USD 1.37B 7.8M Jun/2026
Bruker USD 1.82B 153.5M Jun/2026
Danaher USD 26.56B 8.07B Jun/2026
Illumina USD 2.54B 9M Mar/2026
J&J USD 54.99B 7.05B Mar/2026
Mettler Toledo International USD 2.23B 76.47M Mar/2026
Myriad Genetics USD 59.3M 19.7M Mar/2025
OraSure Technologies USD 782K 465K Jun/2024
Pacific Biosciences Of California USD 892.24M 653K Dec/2023
Quest Diagnostics USD 6.41B 179M Mar/2026
Quidel USD 2.87B 40.8M Mar/2026
Repligen USD 690.94M 144.36M Jun/2026
Revvity USD 3.35B 48.03M Mar/2026
Standard Biotools USD 29.49M 2.1M Mar/2026
Thermo Fisher Scientific USD 43.16B 3.78B Mar/2026
Veracyte USD 39.33M 321K Mar/2026
Waters USD 5.57B 4.08B Mar/2026